A panel of monoclonal antibodies to human intermediate filament proteins was tested on an unselected series of 246 neoplasms. The antibody panel includes two different anti-cytokeratin antibodies, an anti-vimentin antibody, and an anti-neurofilament antibody (Gown and Vogel, Am J Pathol 114:309, 1984). The studies were done on Carnoy's or methacarn-fixed, paraffinembedded tissue. When used as a panel, they can unequivocally distinguish carcinomas, melanomas, and lymphomas. All carcinomas react with at least one of the anti-cytokeratin antibodies, and carcinomas can be subtyped based upon the pattern of reactivity with the two anti-cytokeratin antibodies. Melanomas react only with the anti-vimentin antibody, and lymphomas react with none of the antibodies. Neural and neuroendocrine tumors can be identified with the anti-neurofilament antibody. A minority of neoplasms, including lymphomas, seminomas, and some sarcomas, do not react with any of the antibodies. These antibodies are reliable diagnostic reagents that are useful in distinguishing different categories of human tumors.
Antibody GOWN AND VOGEL

Results
The pattern of reactivity of different tumors with the individual members of the monoclonal antibody panel is defined as follows: ++++, a uniform positivity of all, or nearly all (>90%) of the tumor cell population; ++, a "heterogenous" pattern, with a subpopulation of the tumor cells, ranging from 30 to 80%, displaying strong immunoreactivity, and the remaining population of tumor cells nonreactive; ±, a minor (<10%) fraction of the tumor cells displaying immunoreactivity. Examples of these various patterns are given in the figures. Results are summarized in Tables 2 and 3 , in which the tumors are grouped according to their patterns of reactivity with the panel of monoclonal antibodies.
Carcinomas (Table 2)
Every epithelial tumor, i.e., carcinoma, reacts with either or both of the anti-cytokeratin antibodies. Based upon reactivity with the two anti-cytokeratin antibodies, four groups of carcinomas can be distinguished:
Group 1. Tumors Uniformly Positive with Anti-Cytokeratin 34flE12 and Largely
Negative with Anti-Cytokeratin 55/37/77. This group includes only squamous cell carcinomas (Fig. 1) .
Group 2. Tumors Uniformly Positive with Both AntiCytokeratins 55/37/77 and 34&E12. The majority of this group corresponds to ductal carcinomas, most notably those of the breast (Fig. 2) , pancreas, bile duct, and salivary gland. Also included in this group are transitional cell carcinomas of the bladder and nasopharynx, thymomas (Fig. 3) , and mesotheliomas (see below).
Group 3. Tumors Uniformly Positive with Anti-Cytokeratin 55/37/77 and Variably Positive with Anti-Cytokeratin 34&E12. These include adenocarcinomas of the ovary (Fig. 4) (Fig. 6) , and all neuroendocrine tumors, including carcinoids and small cell tumors.
The vast majority of carcinomas are vimentin and neurofilament negative, but exceptions to this finding exist. Adenocarcinomas of the endometrium, thyroid, kidney, and salivary gland, as well as mesotheliomas, exhibit focal reactivity with the anti-vimentin antibody. These lesions are also cytokeratin positive, so their epithelial nature is not "masked" by the presence of vimentin.
Neuroendocrine tumors (carcinoid tumors, small cell carcinomas, and pancreatic islet cell tumors) are recognized by a single anticytokeratin antibody, 35/3H1 1. Of these, only some reacted with the neurofilament antibody. These are the only epithelial tumors found that react with neurofilament antibodies. (Table 3) Group 5. Mesenchymal Tumors. The vast majority of the sarcomas tested were strongly vimentin positive and nonreactive with the other antibodies. However, a vimentin-positive synovial sarcoma was focally positive with both anti-cytokeratin antibodies. None of the sarcomas reacted with neurofilament antibodies.
Nonepithelial Tumors
Group 6. Melanomas. All the melanomas tested were vimentin positive and cytokeratin and neurofilamentnegative (Fig. 7) .
Group 7. Neural Tumors. Three neurofilament-positive tumors were negative with cytokeratin and vimentin antibodies. An esthesioneuroblastoma showed heterogeneous reactivity with the neurofilament marker, while a pheochromocytoma and paraganglioma showed focal "dot-like" reactivity ( Fig. 8) . 
* n * number of cases. 
• n = number of cases. t Vimentin positivity variable, ranging from ± to + + + + . ies, to paraffin-embedded surgical pathology specimens representing a wide range of neoplasms from various sites. Results of this investigation confirm that monoclonal antibodies to human intermediate filament proteins can be used as an aid in the histologic subclassification of human neoplasms. In most cases, the cytoskeletal phenotype of tumors resembles that of the normal counterpart cells and is largely independent of the degree of differentiation exhibited by the tumor. Our experience has demonstrated that there are several clinical situations in which these antibodies have been particularly helpful in differential diagnosis:
(1) Differentiation of Poorly Differentiated Carcinomas from Lymphomas or Melanomas. All carcinomas display immunoreactivity with at least one of the cytokeratin monoclonal antibodies, whereas the latter two neoplasms do not. Although it has been demonstrated previously that melanomas express vimentin rather than cytokeratins, 31 the unique feature of our monoclonal anti-vimentin antibody 43/3E8 {i.e., its nonreactivity with lymphoid cells) permits further discrimination. These three neoplasms exhibit different patterns of reactivity with the antibody panel. Additionally, it is possible to increase the specificity of the antibody panel by including a commercially available monoclonal T-200 antibody (Dako) that reacts specifically with lymphomas in paraffin-embedded sections. With the addition of this antibody, melanomas, carcinomas, and lymphomas each display a unique "phenotype" (Table 4) .
(2) Subclassification of Carcinomas. As can be seen from Table 2 , carcinomas can be categorized into "groups," based upon the pattern of reactivity with the two cytokeratin antibodies. Squamous cell carcinomas possess a unique phenotype (34/3E12-positive, 35/8H11 negative), and even poorly differentiated squamous carcinomas maintain this phenotype (Fig. 1 ). Equal reactivity with both cytokeratin antibodies generally places a tumor in the category of a ductal or transitional cell carcinoma. 3 5/3H11-positive, 34/3E12-negative tumors are either "acinar" type adenomas or adenocarcinomas of simple epithelia (e.g., endometrial carcinomas, renal and hepatocellular carcinomas) or neuroendocrine tumors. Furthermore, the pattern of immunoreactivity with anti-cytokeratin antibodies was often characteristic of a particular neoplasm. For example, in ovarian papillary carcinomas (Fig. 4) , isolated clusters of cells within individual fronds of the tumor were positive with anti-cytokeratin 34/3E12, while there was uniform positivity throughout the tumor with anti-cytokeratin 35/3H11. As a second example, the presence of focal vimentin positivity in cytokeratin-positive carcinomas was seen only in salivary gland, thyroid, renal, endometrium, testicular, and ovarian carcinomas. The presence of cytokeratins in thymomas is useful in distinguishing them from lymphomas. 2 We report here the finding of reactivity of thymoma cells with both cytokeratin monoclonal antibodies. As this particular "cytokeratin phenotype" is shared by mesotheliomas, transitional cell carcinomas, and duct carcinomas, its diagnostic significance is not clear.
(3) Mesothelioma versus Lung Adenocarcinoma. This is a controversial subject, with several authors claiming that antibodies to cytokeratin can be used to differentiate mesotheliomas (cytokeratin-positi ve, CEA-negati ve) from adenocarcinomas(cytokeratin-negative,CEA-positive) 5 ' 33 and others denying this. 1, 14 Our studies confirm the work of Wu et al., 41 demonstrating clearly that mesotheliomas do express cytokeratins. Epithelioid mesotheliomas (those often confused with adenocarcinomas) react strongly with both cytokeratin antibodies, whereas those lung adenocarcinomas examined tend to react more strongly with anti-cytokeratin 35/3H11. Mesotheliomas, unlike lung adenocarcinomas, also display variably positive vimentin immunoreactivity. In addition, more recently analyzed fibroblastic mesotheliomas react only with anti-cytokeratin 35/3H11 but also expressed vimentin (data not shown). Analysis of further mesothelial specimens will be necessary to determine the diagnostic value of these preliminary findings.
(4) Synovial Sarcoma versus Fibrosarcoma. Synovial sarcomas, as first revealed by Miettinen et a/., 23 ' 24 are alone among sarcomas in expressing cytokeratins in addition to vimentin. In the case examined here, the tumor was reactive, at least focally, with both anti-cytokeratin antibodies. Recently, cytokeratin positivity has been described in epithelioid sarcomas 4 ; we have not had the opportunity of examining this neoplasm.
(5) Diagnosis of Neural and Neuroendocrine Tumors. In agreement with previous workers, 27, 36 we have found neurofilaments to be localized to only a subset of neural and neuroendocrine tumors. All neuroendocrine tumors in our studies have displayed a 34/3E12-negative, 35/3H11-positive cytokeratin phenotype. In addition, some of these tumors are neurofilament positive. Thus, one can use the cytokeratin and neurofilament antibodies to verify the diagnosis of small cell carcinoma. Other markers such as chromogranin 39 and neuron-specific enolase 3 are also helpful in this regard. Our results differ from those of Lehto et a/., 21 who found that oat cell carcinomas were cytokeratin negative. This discrepancy may result from differences in the specificities of the cytokeratin antibodies used in these studies (see below).
Three major classes of tumors do not react with any of the panel of four antibodies. These include (1) lymphomas, (2) seminomas, and (3) a subclass of sarcomas. It is possible that this finding results from a phenomenon similar to that occurring in lymphomas, in which vimentin is present in the cytoplasm but is not reactive with the monoclonal antibody. The vimentin in these tumor cells may be altered by phosphorylation or glycosylation adversely affecting immunoreactivity. Alternatively, these tumor cells may possess a different intermediate filament protein such as desmin, though preliminary results (not shown) with an anti-desmin antibody have been negative. Finally, as with cells in the very early embryo, 20 they may possess no intermediate filaments.
Fixation and Immunoreactivity
It has been our experience that these antibodies work quite consistently with the ABC immunoperoxidase system in Carnoy's or methacarn-fixed, paraffin-embedded sections of routine surgical pathology material. The cytokeratin antibodies, and to a more limited degree, the vimentin antibody, can work on the more standard formaldehyde-fixed, paraffin-embedded material if the tissue is treated extensively (30 minutes or longer) with 0.1 % Pronase® in phosphate buffer, although results are less consistent. We currently ask our residents to place representative portions of all tumors in methacarn, in addition to the standard fixative. Although this fixative was specifically selected to optimize intermediate filament immunocytochemistry, we also have noted that antigenic preservation for a wide variety of other proteins is either equivalent or superior to that of formaldehyde (Gown and co-workers, manuscript in preparation). We also find that the crispness of nuclear detail and the clarity of the tissue patterns often complements the histology observed in formaldehyde-fixed tissues. As tissue can be stored for up to a week or more in methacarn without significant shrinkage, 28 it is possible to store tissue in this fixative pending analysis of the formaldehyde-fixed blocks. We have detected only minor differences in antigenic preservation between methacarn and Carnoy's fixed tissue, though the former seems to optimally preserve vimentin immunoreactivity.
Comparison of Different Anti-Cytokeratin Antibodies
Standardization of cytokeratin antibodies is currently a great problem to most pathologists wishing to use them in tumor diagnosis. At least 20 different human cytokeratin peptides have been catalogued, 25 and a variety of monoclonal antibodies have been made to different cytokeratin preparations. - 40 This has led to a confusing situation with regard to standardization of cytokeratin antibodies and their reactivities with different carcinomas. However, some generalizations can be made (see Table 5 ).
The first class of antibodies in Table 5 react with all carcinomas, both squamous and nonsquamous. Neither of the cytokeratin antibodies described in this article falls into this category.
The second class of antibodies react only with squamous cell carcinomas and not tumors of ductal or simple {i.e., nonsquamous) epithelium. Antibody 34/3B4, described elsewhere, 13 falls into this category. The third class contains those antibodies reacting with all nonsquamous epithelial tumors. These generally correspond to antibodies that react with cytokeratins 8 and/ or 18 of the Moll catalog. 25 Antibody 35(8H11 falls into this category.
The final class consists of antibodies reactive with both squamous and ductal neoplasms but not those of "simple" epithelium, as does antibody 34/3E12.
It is difficult to identify where polyclonal cytokeratin antibodies would fit in the above scheme. Many, in our experience, react like Class 2 or Class 4 (squamous or squamous and ductal reactivity only), though specificities may vary considerably from antibody to antibody.
Work presented here and by others clearly demonstrates that cytokeratin antibodies exist that recognize all epithelial tumors. Single anti-cytokeratin antibodies, or a combination of antibodies such as 34/3E12 and 35/3H11, can be used as a general screen for all carcinomas. Indeed, it may be that cytokeratin immunoreactivity is the sina qua non of an epithelial tumor. We believe it to be a more specific finding than electron microscopic evidence of tonofilaments, which may be indistinguishable from clumps of other classes of intermediate filaments'' or desmosomes, which are present in myocardial cells 8 and meningeal cells. 9 In addition, cytokeratin appears to be a more general epithelial marker than EMA (epithelial membrane antigen) because EMA is not expressed by some carcinomas such as basal cell carcinomas and hepatocellular carcinomas. 35 Because of the complexity of the cytokeratin family and antibodies made to these molecules, it is important that the specificity of an anti-cytokeratin antibody be known when it is used diagnostically. Before a tumor is described as cytokeratin-negative, one must be certain that the antibody is capable of recognizing that particular tumor. Discrepancies in the literature about anti-cytokeratin reactivity of various carcinomas probably result from differences in the specificities of the antibodies used by different investigators.
The generation of additional monoclonal antibodies, such as those to additional cytokeratin peptides, to expand our antibody panel promises to add greater discriminating ability to the screening procedure. Rather than relying on the "hit or miss" ability of a single antibody to define a particular neoplasm, we believe that each neoplasm is better characterized by its pattern of reactivity with a constellation of antibodies, in which antibodies to intermediate filament proteins play a pivotal role.
